Making Genetics employs EpiTYPER® DNA methylation analysis technology (formerly Sequenom®). This method allows you to interrogate dozens of CpG sites in amplicons of up to 600 bp and detect down to 5%on differences in methylation.

EpiTYPER® starts with bisulfite treatment of genomic DNA, followed by PCR amplification of target regions using primers with T7 promoter label. The in vitro RNA transcription is performed, followed by a base-specific RNA cleavage. Finally, the cleavage products are analyzed using MALDI-TOF (MassARRAY Analyzer). Methylated and non-methylated cytosine residues in the original genomic DNA are distinguished using EpiTYPER® software.

EpiTYPER® software minimizes manual design and assay optimization, without having to design CpG specific primers. In addition, a streamlined workflow reduces the experimental time and unwanted variability, allowing it to move from bisulfite-treated DNA to data in less than 8 hours..


• Validate epigenomic-wide association studies (EGWAS) across a larger number of samples to determine the predictive value of biomarkers for routine clinical diagnostic use.

• Research differential methylation patterns in development

• Study aberrant methylation changes in tumor initiation and cancer progression

• Study heritable characteristics influenced by the environment of previous generations.

Published articles employing this technology can be consulted HERE.

Contact here for price and availability

Submit to FacebookSubmit to Google PlusSubmit to TwitterSubmit to LinkedIn




ministerio de economía


COD 8 logo wis 130x50